The electromagnetic process $e^{+}e^{-}\to p\bar{p}$ is studied with the initial-state-radiation technique using 7.5 fb$^{-1}$ of data collected by the BESIII experiment at seven energy points from 3.773 to 4.600 GeV. The Born cross section and the effective form factor of the proton are measured from the production threshold to 3.0 GeV/$c^{2}$ using the $p\bar{p}$ invariant-mass spectrum. The ratio of electric and magnetic form factors of the proton is determined from the analysis of the proton-helicity angular distribution.
Banxia Xiexin decoction (BXD) is a traditional prescription widely used to treat gastrointestinal conditions, including gastric cancer. Through network pharmacology, bioinformatics, and molecular docking analysis, this study aimed to investigate the potential mechanism of the antigastric cancer effect of BXD and pave the way for future research. The network pharmacology analysis used BXD index components to improve reliability and validity. Prognosis-related genes identified through Lasso and Cox regression analysis were considered potential BXD core targets for gastric cancer. Functional enrichment analysis was conducted to uncover the potential mechanism of action of BXD in gastric cancer. In addition, molecular docking of the index components of BXD and the core targets was used to validate the results. The present study obtained six index components of BXD and 155 corresponding antigastric cancer targets. ANXA5, CYP19A1, FGF1, and F2 in the prognostic signature model were identified as core targets of the index components of BXD. Protein-protein interaction networks and functional enrichment analysis indicated that proteoglycans in cancer, PI3K-Akt, and other pathways were involved. According to molecular docking results, six index components showed good-to-strong binding affinities to the core targets. The results indicated that the index components of BXD act on multiple pathways and targets of gastric cancer. Our study paved the way for further investigation of the antigastric cancer activity and mechanisms of BXD.
We search for the semi-leptonic decays $\Lambda_c^+ \to \Lambda \pi^+ \pi^- e^+ \nu_e$ and $\Lambda_c^+ \to p K_S^0 \pi^- e^+ \nu_e$ in a sample of 4.5 $\mathrm{fb}^{-1}$ of $e^{+}e^{-}$ annihilation data collected in the center-of-mass energy region between 4.600 GeV and 4.699 GeV by the BESIII detector at the BEPCII. No significant signals are observed, and the upper limits on the decay branching fractions are set to be $\mathcal{B}(\Lambda_c^+ \to \Lambda \pi^+ \pi^- e^+ \nu_e)<3.9\times10^{-4}$ and $\mathcal{B}(\Lambda_c^+ \to p K_S^0 \pi^- e^+ \nu_e)<3.3\times10^{-4}$ at the 90% confidence level, respectively.
Background: Compound Kushen injection (CKI) is a mixture of natural compounds extracted from Radix Sophorae and Smilax glabra Roxb. CKI, as an antitumor preparation, plays a vital role in the clinical treatment of lung and gastrointestinal cancers. Methods: Electronic databases such as the China National Knowledge Infrastructure, Wanfang data, PubMed, EMBASE, and Web of Science were searched for studies. The included studies were evaluated according to the Cochrane Handbook for Systematic Reviews, and meta-analyses were performed using RevMan 5.3 software. Results: Twenty-four randomized controlled trials were selected for meta-analysis. The outcomes showed that CKI adjuvant therapy significantly improved complete remission (CR) and partial response (PR) compared to patients without CKI treatment in gastrointestinal cancers (CR: odds ratio [OR] = 1.76, 95% confidence interval [CI]: [1.29, 2.41], P = .0004; PR: OR = 1.64, 95% CI: [1.29, 2.07], P =.0001), and lung cancer (CR: OR = 2.18, 95% CI: [1.36, 3.51], P = .001); PR: OR = 1.81, 95% CI: [1.31, 2.50], P = .0003). CKI adjuvant therapy had a statistically significant advantage in optimizing life and health status (quality of life [QOL] for gastrointestinal cancers: MD = 1.76, 95% CI: [6.41, 13.80], P = .001, and Karnofsky performance status [KPS] for gastrointestinal cancers: MD = 4.64, 95% CI: [2.72, 6.57], P = .001; KPS for lung cancer: MD = 6.24, 95% CI [1.78, 10.71], P = .006). CKI reduced the pain in lung cancer patients (MD = −1.76, 95% CI: [−1.94, −1.58], P < .00001), increased immunity level (MD = 2.51, 95% CI: [2.17, 2.85], P < .00001), and alleviated the adverse reactions for lung and gastrointestinal cancers (MD = 0.38, 95% CI: (0.32, 0.46); P < .00001). Conclusion: The combination of CKI and chemoradiotherapy for treating lung and gastrointestinal cancer has positive effects on short-term and long-term outcomes and has advantages over chemoradiotherapy alone regarding safety and efficacy.
Using 16 energy points of $e^{+}e^{-}$ annihilation data collected in the vicinity of the $J/\psi$ resonance with the BESIII detector and with a total integrated luminosity of around 100 pb$^{-1}$, we study the relative phase between the strong and electromagnetic amplitudes of $J/\psi$ decays. The relative phase between $J\psi$ electromagnetic decay and the continuum process ($e^{+}e^{-}$ annihilation without the $J/\psi$ resonance) is confirmed to be zero by studying the cross section lineshape of $\mu^{+}\mu^{-}$ production. The relative phase between $J/\psi$ strong and electromagnetic decays is then measured to be $(84.9\pm3.6)^\circ$ or $(-84.7\pm3.1)^\circ$ for the $2(\pi^{+}\pi^{-})\pi^{0}$ final state by investigating the interference pattern between the $J/\psi$ decay and the continuum process. This is the first measurement of the relative phase between $J/\psi$ strong and electromagnetic decays into a multihadron final state using the lineshape of the production cross section. We also study the production lineshape of the multihadron final state $\eta\pi^{+}\pi^{-}$ with $\eta\to\pi^{+}\pi^{-}\pi^{0}$, which provides additional information about the phase between the $J/\psi$ electromagnetic decay amplitude and the continuum process. Additionally, the branching fraction of $J/\psi\to 2(\pi^{+}\pi^{-})\pi^{0}$ is measured to be $(4.73\pm0.44)\%$ or $(4.85\pm0.45)\%$, and the branching fraction of $J/\psi\to\eta\pi^{+}\pi^{-}$ is measured to be $(3.78\pm0.68)\times10^{-4}$. Both of them are consistent with the world average values. The quoted uncertainties include both statistical and systematic uncertainties, which are mainly caused by the low statistics.
We report the first observation of the decay $\Lambda^+_{c}\rightarrow \Sigma^- \pi^+\pi^+\pi^0$, based on data obtained in $e^+e^-$ annihilations with an integrated luminosity of 567~pb$^{-1}$ at $\sqrt{s}=4.6$~GeV. The data were collected with the BESIII detector at the BEPCII storage rings. The absolute branching fraction $\mathcal{B}(\Lambda^+_{c}\rightarrow\Sigma^-\pi^+\pi^+\pi^0)$ is determined to be $(2.11\pm0.33({\rm stat.})\pm0.14({\rm syst.}))\%$. In addition, an improved measurement of $\mathcal{B}(\Lambda^+_{c}\rightarrow\Sigma^-\pi^+\pi^+)$ is determined as $(1.81\pm0.17({\rm stat.})\pm0.09({\rm syst.}))\%$.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
'/%3e%3cpath fill='%23fff' d='m8.751-17.959 10.11 11.373L3.997-9.844l13.94-6.1-7.692 13.129z'/%3e%3c/svg%3e)
